Saturday 17 October 2026
Export BCAX’s income statement to Excel — free account
Bicara Therapeutics Inc.
BCAX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 64.0% and free cash flow fell 73.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
16.78
0.84
−4.77%
Follow BCAX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(26.64%) | (30.88%) | (32.34%) | (41.01%) | |
| (25.61%) | (29.32%) | (30.50%) | (38.38%) | ||
ROIC |
(78.32%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(43.95%) | (35.06%) | (31.09%) | (40.23%) | |
Free Cash Flow per Share |
(2.07) | (1.96) | (1.92) | (1.99) | |
Free Cash Flow |
(113.09) | (107.16) | (116.62) | (135.25) | |
Capital Expenditures |
(0.11) | (0.33) | (0.38) | (0.40) | |
| Other line items | |||||
Cash ROIC |
(16.32%) | (13.13%) | (11.07%) | (14.00%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.93 | 0.77 | 0.74 | 0.73 | |
Depreciation/Fixed assets |
0.81 | 1.23 | 2.22 | 2.85 | |
Capex/Depreciation |
(1.00) | (0.81) | (0.49) | (0.39) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.07) | (1.95) | (1.91) | (1.99) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates